Paraneoplastic Galactorrhea in Childhood T-ALL: An Evaluation of Tumor-derived Prolactin.
T-cell acute lymphoblastic leukemia (T-ALL) comprises 15% of childhood leukemia. Although multiagent pulse chemotherapy has improved event-free survival in recent decades, the lack of reliable prognosticators and high rate of relapse remain a challenge. Described is a novel discovery of tumor-derived hyperprolactinemia in childhood T-ALL through a case associated with paraneoplastic galactorrhea. Prolactin production by tumor cells, although a rare phenomenon, is previously demonstrated in several adult cancers and 2 pediatric malignancies with unknown implications. This is the first report demonstrating tumor-derived prolactin in pediatric T-ALL and offers potential as a disease marker and therapeutic drug target.
Departments of *Pediatrics, Hematology/Oncology ‡Molecular Medicine, UT Health Science Center San Antonio †Greehey Children's Cancer Research Institute §Texas Research Park, San Antonio, TX ∥Dept of Hematology/Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD.
Allison
A
Grimes
Nooshin
N
Mirkheshti
Bandana
B
Chatterjee
Gail
G
Tomlinson
Chatchawin
C
Assanasen
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018771:Arthralgia / Q000209:etiology; D001215:Asparaginase / Q000008:administration & dosage; D002872:Chromosome Deletion; D004317:Doxorubicin / Q000008:administration & dosage; D005221:Fatigue / Q000209:etiology; D005260:Female; D005687:Galactorrhea / Q000097:blood / Q000209:etiology*; D017353:Gene Deletion; D006801:Humans; D009384:Paraneoplastic Endocrine Syndromes / Q000097:blood / Q000209:etiology*; D011092:Polyethylene Glycols / Q000008:administration & dosage; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D011241:Prednisone / Q000008:administration & dosage; D011388:Prolactin / Q000097:blood*; D050783:Proto-Oncogene Proteins c-ets / Q000235:genetics; D012074:Remission Induction; D012097:Repressor Proteins / Q000235:genetics; D014750:Vincristine / Q000008:administration & dosage; D000097764:ETS Translocation Variant 6 Protein
D001215:Asparaginase; D004317:Doxorubicin; D011092:Polyethylene Glycols; D011241:Prednisone; D011388:Prolactin; D050783:Proto-Oncogene Proteins c-ets; D012097:Repressor Proteins; D014750:Vincristine; D000097764:ETS Translocation Variant 6 Protein; C042705:pegaspargase